Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
511 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Depression - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Depression - Pipeline Review, H2 2015', provides an overview of the Depression's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Depression pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Depression - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 8 Depression Overview 9 Therapeutics Development 10 Depression - Therapeutics under Development by Companies 12 Depression - Therapeutics under Investigation by Universities/Institutes 20 Depression - Pipeline Products Glance 23 Depression - Products under Development by Companies 27 Depression - Products under Investigation by Universities/Institutes 38 Depression - Companies Involved in Therapeutics Development 40 Depression - Therapeutics Assessment 127 Drug Profiles 148 Depression - Recent Pipeline Updates 376 Depression - Dormant Projects 453 Depression - Discontinued Products 476 Depression - Product Development Milestones 483 Appendix 491
List of Tables
Number of Products under Development for Depression, H2 2015 29 Number of Products under Development for Depression - Comparative Analysis, H2 2015 30 Number of Products under Development by Companies, H2 2015 32 Number of Products under Development by Companies, H2 2015 (Contd..1) 33 Number of Products under Development by Companies, H2 2015 (Contd..2) 34 Number of Products under Development by Companies, H2 2015 (Contd..3) 35 Number of Products under Development by Companies, H2 2015 (Contd..4) 36 Number of Products under Development by Companies, H2 2015 (Contd..5) 37 Number of Products under Development by Companies, H2 2015 (Contd..6) 38 Number of Products under Investigation by Universities/Institutes, H2 2015 40 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 41 Comparative Analysis by Late Stage Development, H2 2015 42 Comparative Analysis by Clinical Stage Development, H2 2015 43 Comparative Analysis by Early Stage Development, H2 2015 44 Comparative Analysis by Unknown Stage Development, H2 2015 45 Products under Development by Companies, H2 2015 46 Products under Development by Companies, H2 2015 (Contd..1) 47 Products under Development by Companies, H2 2015 (Contd..2) 48 Products under Development by Companies, H2 2015 (Contd..3) 49 Products under Development by Companies, H2 2015 (Contd..4) 50 Products under Development by Companies, H2 2015 (Contd..5) 51 Products under Development by Companies, H2 2015 (Contd..6) 52 Products under Development by Companies, H2 2015 (Contd..7) 53 Products under Development by Companies, H2 2015 (Contd..8) 54 Products under Development by Companies, H2 2015 (Contd..9) 55 Products under Development by Companies, H2 2015 (Contd..10) 56 Products under Investigation by Universities/Institutes, H2 2015 57 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 58 Depression - Pipeline by AB Science SA, H2 2015 59 Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 60 Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 61 Depression - Pipeline by Adamed Sp. z o.o., H2 2015 62 Depression - Pipeline by Addex Therapeutics Ltd, H2 2015 63 Depression - Pipeline by Aequus Pharmaceuticals Inc., H2 2015 64 Depression - Pipeline by Alkermes Plc, H2 2015 65 Depression - Pipeline by Allergan Plc, H2 2015 66 Depression - Pipeline by Alvogen Korea, H2 2015 67 Depression - Pipeline by Amorsa Therapeutics Inc., H2 2015 68 Depression - Pipeline by Anavex Life Sciences Corp., H2 2015 69 Depression - Pipeline by Angelini Group, H2 2015 70 Depression - Pipeline by Angita B.V., H2 2015 71 Depression - Pipeline by ANP Technologies, Inc., H2 2015 72 Depression - Pipeline by Ascendis Pharma A/S, H2 2015 73 Depression - Pipeline by AstraZeneca Plc, H2 2015 74 Depression - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015 75 Depression - Pipeline by BioCrea GmbH, H2 2015 76 Depression - Pipeline by Bionomics Limited, H2 2015 77 Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2015 78 Depression - Pipeline by Bristol-Myers Squibb Company, H2 2015 79 Depression - Pipeline by Calico LLC, H2 2015 80 Depression - Pipeline by Cerecor Inc., H2 2015 81 Depression - Pipeline by Clera Inc., H2 2015 82 Depression - Pipeline by Convergence Pharmaceuticals Ltd., H2 2015 83 Depression - Pipeline by D-Pharm Ltd., H2 2015 84 Depression - Pipeline by Delpor, Inc., H2 2015 85 Depression - Pipeline by Domain Therapeutics SA, H2 2015 86 Depression - Pipeline by e-Therapeutics Plc, H2 2015 87 Depression - Pipeline by Eisai Co., Ltd., H2 2015 88 Depression - Pipeline by Eli Lilly and Company, H2 2015 89 Depression - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 90 Depression - Pipeline by GlaxoSmithKline Plc, H2 2015 91 Depression - Pipeline by GliaCure Inc., H2 2015 92 Depression - Pipeline by H. Lundbeck A/S, H2 2015 93 Depression - Pipeline by Heptares Therapeutics Limited, H2 2015 94 Depression - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2015 95 Depression - Pipeline by Hua Medicine Ltd., H2 2015 96 Depression - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 97 Depression - Pipeline by INSYS Therapeutics, Inc., H2 2015 98 Depression - Pipeline by Intas Pharmaceuticals Ltd., H2 2015 99 Depression - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 100 Depression - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 101 Depression - Pipeline by Johnson & Johnson, H2 2015 102 Depression - Pipeline by KemPharm, Inc., H2 2015 103 Depression - Pipeline by Lead Discovery Center GmbH, H2 2015 104 Depression - Pipeline by Luye Pharma Group Ltd., H2 2015 105 Depression - Pipeline by M et P Pharma AG, H2 2015 106 Depression - Pipeline by Mapreg S.A.S., H2 2015 107 Depression - Pipeline by Meta-IQ ApS, H2 2015 108 Depression - Pipeline by Methylation Sciences Inc., H2 2015 109 Depression - Pipeline by MI.TO. Technology S.r.L., H2 2015 110 Depression - Pipeline by miCure Therapeutics Ltd., H2 2015 111 Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 112 Depression - Pipeline by Neuralstem, Inc., H2 2015 113 Depression - Pipeline by Neurocrine Biosciences, Inc., H2 2015 114 Depression - Pipeline by NeuroNascent, Inc., H2 2015 115 Depression - Pipeline by NeurOp, Inc, H2 2015 116 Depression - Pipeline by Newron Pharmaceuticals S.p.A., H2 2015 117 Depression - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 118 Depression - Pipeline by nLife Therapeutics, S.L., H2 2015 119 Depression - Pipeline by Novartis AG, H2 2015 120 Depression - Pipeline by Omeros Corporation, H2 2015 121 Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 122 Depression - Pipeline by Pfizer Inc., H2 2015 123 Depression - Pipeline by Pherin Pharmaceuticals, Inc., H2 2015 124 Depression - Pipeline by Polleo Pharma Limited, H2 2015 125 Depression - Pipeline by Protagenic Therapeutics Inc., H2 2015 126 Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2015 127 Depression - Pipeline by Richter Gedeon Nyrt., H2 2015 128 Depression - Pipeline by RTI International, H2 2015 129 Depression - Pipeline by Saniona AB, H2 2015 130 Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 131 Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 132 Depression - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 133 Depression - Pipeline by Supernus Pharmaceuticals, Inc., H2 2015 134 Depression - Pipeline by Suven Life Sciences Ltd., H2 2015 135 Depression - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2015 136 Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 137 Depression - Pipeline by Tetra Discovery Partners LLC, H2 2015 138 Depression - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 139 Depression - Pipeline by Trevena, Inc., H2 2015 140 Depression - Pipeline by Turing Pharmaceuticals AG , H2 2015 141 Depression - Pipeline by VistaGen Therapeutics , Inc., H2 2015 142 Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2015 143 Depression - Pipeline by Zogenix, Inc., H2 2015 144 Depression - Pipeline by Zysis Limited, H2 2015 145 Assessment by Monotherapy Products, H2 2015 146 Assessment by Combination Products, H2 2015 147 Number of Products by Stage and Target, H2 2015 149 Number of Products by Stage and Mechanism of Action, H2 2015 158 Number of Products by Stage and Route of Administration, H2 2015 164 Number of Products by Stage and Molecule Type, H2 2015 166 Depression Therapeutics - Recent Pipeline Updates, H2 2015 395 Depression - Dormant Projects, H2 2015 472 Depression - Dormant Projects (Contd..1), H2 2015 473 Depression - Dormant Projects (Contd..2), H2 2015 474 Depression - Dormant Projects (Contd..3), H2 2015 475 Depression - Dormant Projects (Contd..4), H2 2015 476 Depression - Dormant Projects (Contd..5), H2 2015 477 Depression - Dormant Projects (Contd..6), H2 2015 478 Depression - Dormant Projects (Contd..7), H2 2015 479 Depression - Dormant Projects (Contd..8), H2 2015 480 Depression - Dormant Projects (Contd..9), H2 2015 481 Depression - Dormant Projects (Contd..10), H2 2015 482 Depression - Dormant Projects (Contd..11), H2 2015 483 Depression - Dormant Projects (Contd..12), H2 2015 484 Depression - Dormant Projects (Contd..13), H2 2015 485 Depression - Dormant Projects (Contd..14), H2 2015 486 Depression - Dormant Projects (Contd..15), H2 2015 487 Depression - Dormant Projects (Contd..16), H2 2015 488 Depression - Dormant Projects (Contd..17), H2 2015 489 Depression - Dormant Projects (Contd..18), H2 2015 490 Depression - Dormant Projects (Contd..19), H2 2015 491 Depression - Dormant Projects (Contd..20), H2 2015 492 Depression - Dormant Projects (Contd..21), H2 2015 493 Depression - Dormant Projects (Contd..22), H2 2015 494 Depression - Discontinued Products, H2 2015 495 Depression - Discontinued Products (Contd..1), H2 2015 496 Depression - Discontinued Products (Contd..2), H2 2015 497 Depression - Discontinued Products (Contd..3), H2 2015 498 Depression - Discontinued Products (Contd..4), H2 2015 499 Depression - Discontinued Products (Contd..5), H2 2015 500 Depression - Discontinued Products (Contd..6), H2 2015 501
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
